Christopher D. Gocke is an Associate Professor of Pathology, Oncology, and Genetic Medicine at the Johns Hopkins University School of Medicine. He is the Director of the Division of Molecular Pathology, Deputy Director (Vice Chairman) of Personalized Medicine for the Department of Pathology, and co-director of Johns Hopkins Genomics. He received his B.A. in Chemistry from Princeton University and his M.D. in 1985 from the Rutgers Medical School. His residency training in pathology was at the University of Rochester and Stanford University where he was Chief Resident. He completed a fellowship in pathology at Stanford. He is a past Councilor on the Program Directors’ Council of the Association of Molecular Pathology and a member of the NCI’s Investigational Drug Steering Committee. He is a co-principle investigator on two NIH research project cooperative agreements.
Maria R. Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center as the Director of Hematologic Malignancies in 2007 and became the co-leader of the University of Maryland Marlene and Stewart Greenebaum Cancer Center Experimental Therapeutics Program in 2014. She is a Professor of Medicine and a Professor of Molecular Medicine at the University of Maryland School of Medicine. She previously served as the Chief of the Leukemia Section of Roswell Park Cancer Institute and a Professor of Medicine and Associate Professor of Molecular Pharmacology and Cancer Therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences. She is a long-standing member of the CALGB/Alliance for Clinical Trials in Oncology Leukemia and Leukemia Correlative Sciences Core Committees and a member of the Stand Up to Cancer Epigenetics Dream Team. Her laboratory works on mechanisms of drug resistance in acute myeloid leukemia and approaches to overcoming drug resistance and has been funded by the National Cancer Institute, the Leukemia and Lymphoma Society Translational Research Program, and the Department of Veterans Affairs. Her current research focuses on signal transduction pathways in acute myeloid leukemia with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) and preclinical development of novel therapeutic approaches to acute myeloid leukemia with this common and prognostically unfavorable molecular abnormality.
